Fig. 3
From: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Inhibition of cellular viability in patient-derived samples. a CD138+ cells were purified from the bone marrow samples of MM patients (3, 4, 6–8, 11, 14–16). The cytotoxic effects of LC53-0110 (filled rectangle) and ixazomib (open circle) were determined by bioluminescent measurement of cellular ATP using CellTiter-Glo reagent after 48 h of treatment. Results are expressed as % cell viability over DMSO control. b The IC50 values for LC53-0110 treated MM patients